Formulation and delivery of RNA-based vaccines and therapeutics: addressing outstanding questions around safety and purity

“...moving away from this dependence on LNPs is an exciting advance in the field.”

In this interview, Róisin McGuigan, Editor, Nucleic Acid Insights, and Jesse Erasmus, Director of Virology at HDT Bio, discuss current challenges and opportunities in RNA safety, manufacturing, and targeted delivery, and the key ongoing obstacles facing viral and LNP-based delivery modalities.

Please enter your email to access content Read now